Although SEMA3F and SEMA3B are generally regarded as tumor suppressors and methylated SEMA3F has been reported in lung cancers [9], it is neo-expression instead of suppression of SEMA3/Plexin expression that is generally observed in PDACs (see Table 1). This evidence concerns the gene SEMA3B and lung carcinoma.